Current State of Personalized Genitourinary Cancer Radiotherapy in the Era of Precision Medicine

被引:8
|
作者
Kamran, Sophia C. [1 ]
Efstathiou, Jason A. [1 ]
机构
[1] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02115 USA
来源
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
关键词
genitourinary cancer (GU cancer); personalized radiation oncology; precision oncology; prostate cancer; testicular cancer; bladder cancer; renal cell carcinoma; precision medicine; PROSTATE-CANCER; BLADDER-CANCER; PET/CT; TRIAL;
D O I
10.3389/fonc.2021.675311
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Radiation therapy plays a crucial role for the management of genitourinary malignancies, with technological advancements that have led to improvements in outcomes and decrease in treatment toxicities. However, better risk-stratification and identification of patients for appropriate treatments is necessary. Recent advancements in imaging and novel genomic techniques can provide additional individualized tumor and patient information to further inform and guide treatment decisions for genitourinary cancer patients. In addition, the development and use of targeted molecular therapies based on tumor biology can result in individualized treatment recommendations. In this review, we discuss the advances in precision oncology techniques along with current applications for personalized genitourinary cancer management. We also highlight the opportunities and challenges when applying precision medicine principles to the field of radiation oncology. The identification, development and validation of biomarkers has the potential to personalize radiation therapy for genitourinary malignancies so that we may improve treatment outcomes, decrease radiation-specific toxicities, and lead to better long-term quality of life for GU cancer survivors.
引用
收藏
页数:15
相关论文
共 50 条
  • [41] Integrative cancer genomics in the era of precision cancer medicine
    Inazawa, Johji
    Miki, Yoshio
    Nakamura, Yusuke
    JOURNAL OF HUMAN GENETICS, 2021, 66 (09) : 843 - 843
  • [42] Breast cancer screening in the precision medicine era
    Thompson, C. K.
    Fiscalini, A. S.
    Donnellan, P.
    Kaplan, C. P.
    Madlensky, L.
    Eklund, M.
    Ziv, E.
    van't Veer, L. J.
    Tice, J. A.
    Esserman, L. J.
    CANCER RESEARCH, 2016, 76
  • [43] Editorial: Cancer genomics in the era of precision medicine
    Khan, Omar M.
    Mallardo, Domenico
    Decock, Julie
    FRONTIERS IN GENETICS, 2024, 15
  • [44] Orphan Cancer Drugs in the Era of Precision Medicine
    Nabhan, Chadi
    Phillips, Eli G., Jr.
    Feinberg, Bruce A.
    JAMA ONCOLOGY, 2018, 4 (11) : 1481 - 1482
  • [45] Gastrointestinal cancer research in the era of precision medicine
    Lin Shen
    OncologyandTranslationalMedicine, 2017, 3 (01) : 1 - 2
  • [46] Personalised cancer care in the era of precision medicine
    Koczwara, Bogda
    Thornton-Benko, Elysia
    Cohn, Richard J.
    Chan, Raymond J.
    Rhee, Joel
    Joske, David
    Iddawela, Mahesh
    Vardy, Janette L.
    AUSTRALIAN JOURNAL OF GENERAL PRACTICE, 2021, 50 (08) : 533 - 537
  • [47] Cell death in cancer in the era of precision medicine
    Giuseppe Raschellà
    Gerry Melino
    Alessandra Gambacurta
    Genes & Immunity, 2019, 20 : 529 - 538
  • [48] Cell death in cancer in the era of precision medicine
    Raschella, Giuseppe
    Melino, Gerry
    Gambacurta, Alessandra
    GENES AND IMMUNITY, 2019, 20 (07) : 529 - 538
  • [49] A New Era of Prostate Cancer Precision Medicine
    Malik, Adil
    Srinivasan, Sri
    Batra, Jyotsna
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [50] Breast Cancer Prevention in the Era of Precision Medicine
    Narod, Steven A.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2015, 107 (05):